2 recruiting, 2 terminated, 1 completed, 1 withdrawn. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 2, Terminated 2, Completed 1, Withdrawn 1 |
| Phase 1 | 1 | Terminated 1 |
Follow IDH2 Gene Mutation: new trials by email Literature Review of IDH2 Gene Mutation trials Research Report on IDH2 Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers Enasidenib, Venetoclax - Acute Myeloid Leukemia, Relapsed Cancer | Phase 1 / Phase 2 | Terminated | University Health Network, Toronto | 27 | 2020-11-05 | 2024-01-24 |
| IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT Enasidenib - Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | Phase 2 | Completed | Heinrich-Heine University, Duesseldorf | 50 | 2020-08-27 | 2024-09-19 |
| Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation Enasidenib, Hematopoietic Cell Transplantation - Blasts Under 5 Percent of Peripheral Blood White Cells, Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level | Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2019-12-02 | 2021-03-10 | |
| Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation Azacitidine, Enasidenib Mesylate - Acute Bilineal Leukemia, Acute Biphenotypic Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 50 | 2018-09-18 | 2026-09-14 |
| Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis Busulfan, Cyclophosphamide, Fludarabine - Anemia, ASXL1 Gene Mutation | Phase 2 | Terminated | University of Utah | 6 | 2018-03-30 | 2022-05-05 |
| Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome Azacitidine, Enasidenib, Quality-of-Life Assessment - Acute Myeloid Leukemia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 63 | 2018-01-17 | 2026-09-04 |
Leukemia, Myeloid, Acute (5) · Leukemia, Myelomonocytic, Chronic (3) · Myelodysplastic Syndromes (2) · Anemia (1) · Anemia, Refractory, with Excess of Blasts (1) · Leukemia, Biphenotypic, Acute (1) · Multiple Myeloma (1) · Neoplasms (1) · Primary Myelofibrosis (1) · Recurrence (1) · Thrombocytopenia (1)
Hematologic Diseases (6) · Hemic and Lymphatic Diseases (6) · Neoplasms by Histologic Type (6) · Leukemia (5) · Leukemia, Myeloid (5) · Neoplasms (5) · Bone Marrow Diseases (4) · Disease Attributes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Chronic Disease (3) · Myelodysplastic-Myeloproliferative Diseases (3) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphoproliferative Disorders (2)
enasidenib (5) · Azacitidine (2) · Hematopoietic Stem Cell Transplantation (2) · Stem Cell Transplantation (2) · 2-Propanol (1) · Busulfan (1) · Cyclophosphamide (1) · fludarabine (1) · methanesulfonic acid (1) · venetoclax (1)
M.D. Anderson Cancer Center (2) · Heinrich-Heine University, Duesseldorf (1) · Roswell Park Cancer Institute (1) · University Health Network, Toronto (1) · University of Utah (1)
United States (4) · Canada (1) · Germany (1)
Courtney DiNardo (2) · Catherine Lee, MD (1) · Elizabeth Griffiths, MD (1) · Steven Chan, M.D. (1) · Thomas Schroeder, PD Dr. (1)
PMID 35078972, PMID 35973199, PMID 41075807
2019 (1), P30CA016672 (1)